

091-19303-2

For Internal Use Only	Submit 1 Original	OMB Approval No.:
Sec File No. 91 -	and 9 Copies	Expires:

Estimated average burden hours per response: 2.00

RECEIVED

OCT 15 PM 1:52

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 19b-4(e)**

SEC 7 MR

**Information Required of a Self-Regulatory Organization Listing and Trading a New
Derivative Securities Product Pursuant to Rule 19b-4(e) Under the Securities Exchange Act of 1934**

READ ALL INSTRUCTIONS PRIOR TO COMPLETING FORM

Part I Initial Listing Report

1. Name of Self-Regulatory Organization Listing New Derivative Securities Product:

NYSE Arca, Inc.

**SEC
Mail Processing
Section**

2. Type of Issuer of New Derivative Securities Product (e.g., clearinghouse, broker-dealer, corporation, etc.):

Open-end Management Investment Company

OCT 15 2015

3. Class of New Derivative Securities Product:

Investment Company Units

**Washington DC
404**

4. Name of Underlying Instrument:

Loncar Cancer Immunotherapy Index



5. If Underlying Instrument is an Index, State Whether it is Broad-Based or Narrow-Based:

Narrow-Based

6. Ticker Symbol(s) of New Derivative Securities Product:

CNCR

7. Market or Markets Upon Which Securities Comprising Underlying Instrument Trades:

NYSE, NASDAQ

8. Settlement Methodology of New Derivative Securities Product:

Regular way trades settle on T+3/Book entry only held in DTC.

9. Position Limits of New Derivative Securities Product (if applicable):

Not applicable.

Part II Execution

The undersigned represents that the governing body of the above-referenced Self-Regulatory Organization has duly approved, or has duly delegated its approval to the undersigned for, the listing and trading of the above-referenced new derivative securities product according to its relevant trading rules, procedures, surveillance programs and listing standards.

Name of Official Responsible for Form:

Martha Redding

Title:

Senior Counsel and Assistant Secretary

Telephone Number:

(212) 656-2938

Manual Signature of Official Responsible for Form:

(Handwritten Signature)
October 14, 2015

SEC 2449 (1/99)

Act	Securities Exchange Act of 1934
Section	19b-4
Rule	19b-4(e)
Public Availability:	OCT 15 2015



Martha Redding
Senior Counsel
Assistant Corporate Secretary

New York Stock Exchange
11 Wall Street
New York, NY 10005
T + 1 212 656 2938
F + 1 212 656 8101
Martha.Redding@theice.com

SEC
Mail Processing
Section
OCT 15 2015
Washington DC
404

RECEIVED
OCT 15 PM 1:47
SEC / MR

Via Overnight Mail

October 14, 2015

Ms. Gail Jackson
US Securities and Exchange Commission
Division of Trading and Markets
Station Place – Building I
100 F Street, N.E. – Room 6628
Washington, DC 20549

Re: 19b-4(e) – Transmittal

Dear Ms. Jackson:

Enclosed for filing pursuant to Section 19(b) of the Securities Exchange Act of 1934 and Rule 19b-4 thereunder, please find an original and nine copies of Form 19b-4(e) with respect to the securities listed below.

- First Trust Emerging Markets Small Cap AlphaDEX Fund (FEMS)**
- First Trust Developed Markets ex-US Small Cap AlphaDEX Fund (FDTS)**
- First Trust Latin America AlphaDEX Fund (FLN)**
- First Trust Europe AlphaDEX Fund (FEP)**
- First Trust Asia Pacific Ex-Japan AlphaDEX Fund (FPA)**
- First Trust Emerging Markets AlphaDEX Fund (FEM)**
- First Trust Developed Markets Ex-US AlphaDEX Fund (FDT)**
- Loncar Cancer Immunotherapy ETF (CNCR)**

If you have any questions, please do not hesitate to call me at (212) 656-2938.

Sincerely,

Enclosures

Act	Securities Exchange Act of 1934
Section	19b-4
Rule	19b-4(e)
Public Availability:	OCT 15 2015